Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal.
作者信息
Schepis Ty S
机构信息
Department of Psychology, Texas State University, San Marcos, Texas, USA.
Translational Health Research Center, Texas State University, San Marcos, Texas, USA.
出版信息
Addiction. 2025 Feb;120(2):251-252. doi: 10.1111/add.16725. Epub 2024 Dec 10.
Abstract
摘要
相似文献
1
Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal.关于凯丹等人的评论：利用机会扩充物质使用障碍治疗手段。
Addiction. 2025 Feb;120(2):251-252. doi: 10.1111/add.16725. Epub 2024 Dec 10.
2
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.葡萄糖依赖性促胰岛素多肽和/或胰高血糖素样肽-1受体激动剂处方与阿片类药物和酒精使用障碍患者物质相关结局之间的关联：一项真实世界数据分析。
Addiction. 2025 Feb;120(2):236-250. doi: 10.1111/add.16679. Epub 2024 Oct 16.
3
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review.GLP-1 激动剂治疗物质使用障碍患者的疗效：范围综述。
J Addict Med. 2024;18(5):488-498. doi: 10.1097/ADM.0000000000001347. Epub 2024 Aug 1.
4
Translating the nuanced risk for substance use among adolescents treated for attention-deficit/hyperactivity disorder (ADHD) into clinical practice: a commentary on McCabe et al. (2023).将接受注意力缺陷多动障碍 (ADHD) 治疗的青少年物质使用风险的细微差别转化为临床实践：对 McCabe 等人（2023 年）的评论。
J Child Psychol Psychiatry. 2024 Jan;65(1):112-115. doi: 10.1111/jcpp.13888. Epub 2023 Sep 5.
5
Kratom as a potential substance use disorder harm reduction agent.Kratom 作为一种潜在的物质使用障碍减少伤害的药物。
Front Public Health. 2024 May 30;12:1416689. doi: 10.3389/fpubh.2024.1416689. eCollection 2024.
6
Opportunities for Identifying and Addressing Unhealthy Substance Use in Rural Communities: A Commentary on Cucciare et al (2017).识别和解决农村社区有害物质使用问题的机会：对库恰雷等人（2017年）的评论
Subst Abuse. 2018 Oct 16;12:1178221818805980. doi: 10.1177/1178221818805980. eCollection 2018.
7
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.胰高血糖素样肽-1（GLP-1）受体激动剂对药物和酒精所致物质使用障碍（SUD）相关行为影响的系统评价。
Physiol Behav. 2019 Jul 1;206:232-242. doi: 10.1016/j.physbeh.2019.03.029. Epub 2019 Apr 1.
8
GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.GIP 和 GLP-2 共同改善人体的骨转换，支持 GIPR-GLP-2R 双重激动剂作为未来骨质疏松症的治疗方法。
Pharmacol Res. 2022 Feb;176:106058. doi: 10.1016/j.phrs.2022.106058. Epub 2022 Jan 4.
9
GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder.胰高血糖素样肽-1受体激动剂：治疗酒精使用障碍的积极信号。
J Gen Intern Med. 2025 Sep;40(12):2997-2999. doi: 10.1007/s11606-025-09498-3. Epub 2025 Apr 24.
10
Emerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists.物质使用障碍治疗中的新兴疗法：聚焦胰高血糖素样肽-1受体激动剂、D3R拮抗剂和促肾上腺皮质激素释放因子拮抗剂。
J Integr Neurosci. 2025 Apr 24;24(4):26361. doi: 10.31083/JIN26361.
本文引用的文献
1
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.葡萄糖依赖性促胰岛素多肽和/或胰高血糖素样肽-1受体激动剂处方与阿片类药物和酒精使用障碍患者物质相关结局之间的关联：一项真实世界数据分析。
Addiction. 2025 Feb;120(2):236-250. doi: 10.1111/add.16679. Epub 2024 Oct 16.
2
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.胰高血糖素样肽-1（GLP-1）受体激动剂在物质使用障碍中的潜在作用：一项随机试验的系统评价。
Drug Alcohol Depend. 2024 Nov 1;264:112424. doi: 10.1016/j.drugalcdep.2024.112424. Epub 2024 Sep 7.
3
Novel therapeutics in development for the treatment of stimulant-use disorder.用于治疗兴奋剂使用障碍的新型治疗方法。
Curr Opin Neurobiol. 2024 Aug;87:102898. doi: 10.1016/j.conb.2024.102898. Epub 2024 Aug 2.
4
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review.GLP-1 激动剂治疗物质使用障碍患者的疗效：范围综述。
J Addict Med. 2024;18(5):488-498. doi: 10.1097/ADM.0000000000001347. Epub 2024 Aug 1.
5
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.司美格鲁肽和替西帕肽可减少肥胖人群的饮酒量。
Sci Rep. 2023 Nov 28;13(1):20998. doi: 10.1038/s41598-023-48267-2.
6
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.胰高血糖素样肽-1受体激动剂是治疗酒精和物质使用障碍的有前景但未经证实的疗法。
Nat Med. 2023 Dec;29(12):2993-2995. doi: 10.1038/s41591-023-02634-8.
7
Analysis of the UK Government's 10-Year Drugs Strategy-a resource for practitioners and policymakers.英国政府 10 年毒品战略分析——从业者和政策制定者的资源。
J Public Health (Oxf). 2023 Jun 14;45(2):e215-e224. doi: 10.1093/pubmed/fdac114.
8
Barriers and Facilitators to Substance Use Disorder Treatment: An Overview of Systematic Reviews.物质使用障碍治疗的障碍与促进因素：系统评价综述
Subst Abuse. 2022 Aug 29;16:11782218221118462. doi: 10.1177/11782218221118462. eCollection 2022.
9
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.胰高血糖素样肽 1（GLP-1）在成瘾障碍中的作用。
Br J Pharmacol. 2022 Feb;179(4):625-641. doi: 10.1111/bph.15677.
10
Cannabis use and cannabis use disorder.大麻使用和大麻使用障碍。
Nat Rev Dis Primers. 2021 Feb 25;7(1):16. doi: 10.1038/s41572-021-00247-4.
Zotero 插件